The Hydroxypropyl-β-Cyclodextrin-Minoxidil Inclusion Complex Improves the Cardiovascular and Proliferative Adverse Effects of Minoxidil in Male Rats: Implications in the Treatment of Alopecia

This meta-analysis found that dutasteride was more effective than finasteride in increasing hair count and improving photographic assessments for men with androgenetic alopecia, while both drugs had similar rates of sexual dysfunction-related adverse effects.

This review explored the new and emerging treatments for androgenetic alopecia and alopecia areata, finding that JAK inhibitors show promise for alopecia areata, while advancements in stem-cell research may eventually lead to new and improved treatments for androgenetic alopecia.

This review discusses the research supporting the approval and use of minoxidil for androgenic alopecia and reports no new clinical results, emphasizing recent findings and developments.

This study found that a topical solution combining 0.25% finasteride with 3% minoxidil significantly improved hair growth, as measured by hair density, diameter, and global assessment, in men with androgenetic alopecia, compared to 3% minoxidil alone, over 24 weeks without systemic adverse effects reported.

This study found that low-level laser therapy was the most effective non-surgical treatment for androgenetic alopecia, although the overall quality of evidence supporting various therapies was generally low.

This study suggests that minoxidil may enhance hair growth by stimulating adipose-derived stem cell motility and growth factor secretion, promoting dermal papilla cell proliferation and accelerating anagen induction.

In this study, adding low-level light therapy to minoxidil significantly improved hair regrowth and patient satisfaction in treating androgenetic alopecia compared to minoxidil alone.

This research investigated aqueous alginate-based hydrogels for delivering minoxidil and reported that using hydroxypropyl-β-cyclodextrin (HP-β-CD) with molar substitution 0.65 significantly enhanced minoxidil's solubility and skin permeability without damaging the epidermis, suggesting potential as an alternative to commercial minoxidil solutions.

This study found that the MXD/HP-β-CD GEL formulation promoted greater hair growth and improved gene expression related to hair growth in male rats compared to MXD solution or control groups.

This study found that a novel effervescent formulation significantly increased minoxidil sulphate accumulation in hair follicles and skin compared to a standard minoxidil solution.

This study found that finasteride was associated with more reproductive adverse effects, including sexual dysfunction in men and fetal harm in women, compared to minoxidil in reported alopecia cases.

This study found no evidence of androgen deficiency or decreased peripheral androgen action in men with persistent sexual symptoms after finasteride use, but identified links to depressed mood and abnormal brain function.

This article reviews treatment options for androgenetic alopecia and suggests that therapy should be personalized and targeted at various pathophysiological aspects, but reports no new clinical findings.

This study reported that using 5% minoxidil topical foam twice daily improved hair density and width in both the frontotemporal and vertex regions of men with moderate androgenetic alopecia.

This study found that both topical and oral finasteride significantly reduced plasma DHT after one week, with lower finasteride plasma exposure for the topical formulation.

This study evaluated new aqueous gel formulations of minoxidil without irritants and found that the calcium alginate gel showed the best performance in terms of drug release and skin permeation.

This pilot study found that a multimodal minoxidil microemulsion with diclofenac and tea tree oil was more effective and safer than minoxidil alone for treating androgenic alopecia over 32 weeks.

This review assessed available treatments for female pattern hair loss and found that minoxidil improved hair regrowth compared to placebo, though high-quality evidence was limited for other interventions.

This study found that daily oral finasteride may increase hair count and improve hair appearance assessments in men with androgenetic alopecia, but it also appears to raise the risk of sexual dysfunction.

This study found that a new 5% minoxidil foam formulation significantly increased hair counts and improved hair loss condition in men with androgenetic alopecia over 16 weeks compared to placebo.

Minoxidil use in children may cause heart issues.

In this 48-week trial, 5% topical minoxidil was more effective than both 2% minoxidil and placebo in promoting hair growth in women with female pattern hair loss, with notable improvements in nonvellus hair count and hair growth assessments.

This study found that minoxidil stimulates hair follicle growth by promoting dermal papilla cell survival and activating ERK and Akt pathways, which leads to increased proliferation and reduced cell death.

This article reviews the mechanisms by which minoxidil stimulates hair growth and reports no new clinical findings.

This case report describes fetal malformations and placental abnormalities in a pregnant woman who applied minoxidil topically, suggesting potential risks of its use during pregnancy.

This study found that combining oral finasteride with topical minoxidil resulted in the greatest improvement in hair growth for male patients with androgenetic alopecia, compared to using any single treatment.

In this study, topical minoxidil was reported to increase fenestration in follicular capillary walls around anagen hair bulbs in male rats.

People with hair loss have more androgen receptors and enzymes in certain follicles, with men and women showing different patterns.

This study found that topical minoxidil increased heart rate and had significant effects on cardiac volumes and mass compared to placebo, but its long-term safety remains uncertain.

This study found that both 2% and 3% minoxidil resulted in a significant increase in hair counts for participants with androgenetic alopecia over 12 months.

Minoxidil can lower blood pressure in some people.

Minoxidil increases blood flow in balding scalps, possibly reversing hair loss.